Page last updated: 2024-12-09

dimethyloxalylglycine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dimethyloxallyl glycine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
GlycinegenusA non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID560326
CHEMBL ID92309
CHEBI ID102218
SCHEMBL ID3700532
MeSH IDM0481320

Synonyms (49)

Synonym
n-methoxycarbonylmethyl-oxalamic acid methyl ester
CHEMBL92309
2-(methoxycarbonylmethylamino)-2-oxo-acetic acid methyl ester
glycine, n-(methoxyoxoacetyl)-, methyl ester
oxamic acid, (carboxymethyl)-, dimethyl ester (7ci)
glycine, n-(2-methoxy-1,2-dioxoethyl)-, methyl ester
89464-63-1
dimethyloxallyl glycine
glycine, n-(methoxyoxoacetyl)-, methyl ester (9ci)
NCGC00163397-01
NCGC00163397-02
NCGC00163397-03
methyl 2-[(2-methoxy-2-oxoethyl)amino]-2-oxoacetate
FT-0650635
CHEBI:102218
dimethyloxalylglycine ,
n-oxalylglycine dimethyl ester
methyl n-[methoxy(oxo)acetyl]glycinate
methyl n-(2-methoxy-2-oxoacetyl)glycinate
n-(2-methoxy-2-oxoacetyl)glycine methyl ester
dmog
AKOS006227635
AB22926
S7483
CCG-208674
HY-15893
SCHEMBL3700532
methyl[(2-methoxy-2-oxoethyl)amino](oxo)acetate
methyl 2-(2-methoxy-2-oxoethylamino)-2-oxoacetate
methyl 2-((2-methoxy-2-oxoethyl)amino)-2-oxoacetate
dimethyloxaloylglycine
AC-32922
HMS3402K19
Q27178902
DTXSID80339961
dmog, >=98% (hplc)
mfcd05865098
dimethyloxaloylglycine (dmog)
dimethyl oxaloylglycine
dimethyloxaloylglycine(dmog)
AS-40798
BCP09050
A13998
n-(methoxyoxoacetyl)-glycine, methyl ester
n-(methoxyoxoacetyl)-glycine methyl ester
D5480
methyl [(2-methoxy-2-oxoethyl)carbamoyl]formate
EN300-141546
Z275980698

Research Excerpts

Effects

ExcerptReferenceRelevance
"Dimethyloxalylglycine (DMOG) has been used to promote angiogenesis in experimental animal models, however, comparable approaches for canine MSCs are not sufficient."( Enhanced angiogenic activity of dimethyloxalylglycine-treated canine adipose tissue-derived mesenchymal stem cells.
An, JH; Chae, HK; Kim, SM; Li, Q; Nam, A; Ryu, MO; Song, WJ; Yang, JI; Youn, HY, 2019
)
1.52

Dosage Studied

ExcerptRelevanceReference
"Human keratinocyte cells (HKCs) were isolated from child or adult foreskins and irradiated with LED light with a wavelength of 640 nm and a dosage of 12 or 24 J/cm(2)."( Light-Emitting Diode Irradiation (640 nm) Regulates Keratinocyte Migration and Cytoskeletal Reorganization Via Hypoxia-Inducible Factor-1α.
Cheng, B; Huang, C; Qian, SL; Sun, LY, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitorAn EC 1.14.11.* (oxidoreductase acting on paired donors, 2-oxoglutarate as one donor, incorporating 1 atom each of oxygen into both donors) inhibitor that interferes with the action of hypoxia-inducible factor-proline dioxygenase (EC 1.14.11.29).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
glycine derivativeA proteinogenic amino acid derivative resulting from reaction of glycine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
methyl esterAny carboxylic ester resulting from the formal condensation of a carboxy group with methanol.
secondary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency39.81070.003245.467312,589.2998AID2517
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency0.39811.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID160200Inhibition of prolyl 4-hydroxylase; No data1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
Novel inhibitors of prolyl 4-hydroxylase. 3. Inhibition by the substrate analogue N-oxaloglycine and its derivatives.
AID426471Inhibition of JMJD2-mediated H3K9 demethylation in human 293T cells at 2.5 mM2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Synthesis and activity of N-oxalylglycine and its derivatives as Jumonji C-domain-containing histone lysine demethylase inhibitors.
AID1763199Inhibition of TET in human THP-1 cells assessed as reduction in 5hmc/5mc level at 25 uM incubated for 12 hrs by dot blot analysis relative to control2021Bioorganic & medicinal chemistry, 06-01, Volume: 39SAR insights into TET2 catalytic domain inhibition: Synthesis of 2-Hydroxy-4-Methylene-pentanedicarboxylates.
AID426470Inhibition of JMJD2-mediated H3K36 demethylation in human 293T cells at 2.5 mM2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Synthesis and activity of N-oxalylglycine and its derivatives as Jumonji C-domain-containing histone lysine demethylase inhibitors.
AID426469Inhibition of JMJD2C-mediated H3K36 demethylation in human 293T cells at 2.5 mM2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Synthesis and activity of N-oxalylglycine and its derivatives as Jumonji C-domain-containing histone lysine demethylase inhibitors.
AID1763200Inhibition of TET in human THP-1 cells assessed as reduction in 5hmc/5mc level at 50 uM incubated for 12 hrs by dot blot analysis relative to control2021Bioorganic & medicinal chemistry, 06-01, Volume: 39SAR insights into TET2 catalytic domain inhibition: Synthesis of 2-Hydroxy-4-Methylene-pentanedicarboxylates.
AID426468Inhibition of JMJD2C-mediated H3K9 demethylation in human 293T cells at 2.5 mM2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Synthesis and activity of N-oxalylglycine and its derivatives as Jumonji C-domain-containing histone lysine demethylase inhibitors.
AID1763201Inhibition of TET in human THP-1 cells assessed as reduction in 5hmc/5mc level at 100 uM incubated for 12 hrs by dot blot analysis relative to control2021Bioorganic & medicinal chemistry, 06-01, Volume: 39SAR insights into TET2 catalytic domain inhibition: Synthesis of 2-Hydroxy-4-Methylene-pentanedicarboxylates.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (4.17)18.2507
2000's1 (4.17)29.6817
2010's15 (62.50)24.3611
2020's7 (29.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.83 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index6.19 (4.65)
Search Engine Demand Index30.30 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other24 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]